Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$20.77 USD
-0.54 (-2.53%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $20.80 +0.03 (0.14%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Denali Therapeutics Inc. [DNLI]
Reports for Purchase
Showing records 61 - 80 ( 185 total )
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
A Snapshot of Novel Targets in Parkinson?s Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
First Glimpse at DNL343 in ALS Patients, As DNLI Advances Efforts
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Freshly Re-Stocked Balance Sheet and A Whole Lot Of Pipeline - 3Q22 Highlights
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Setting Expectations for the DNL593?s Part B; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
The Beginning of an Era of Anti-Amyloids and Combination Therapies in Alzheimer''s Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
SSIEM Interim Data Maintains the Best-in-Class Profile of DNL310 and Keeps Accelerate Approval Path Open?Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Consistent Safety and Biomarker Data from DNL310 Might be Ripe for an Accelerated Approval; Reit. Buy and $105 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Next DNL310 Update Just Around The Corner - 2Q22 Highlights
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department